Conor Medsystems v. Angiotech
This article was originally published in The Gray Sheet
Executive Summary
Conor seeks revocation of Angiotech patent (EP0706376) related to stents coated with paclitaxel and a polymeric carrier in the UK's High Court of Justice. Angiotech and licensee Boston Scientific recently brought an infringement suit against stent developer Conor in The Netherlands (1"The Gray Sheet" Feb. 7, 2005, p. 7)...
You may also be interested in...
Conor Takes Stent Defense Down Under With Patent Invalidation Suit
Conor MedSystems' proactive efforts to protect its CoStar paclitaxel-eluting stent have expanded to Australia
Taxus Companies Clash With Conor Over European Paclitaxel Patent
Boston Scientific and Angiotech Pharmaceuticals are attempting to block Conor Medsystems' use of clinical trial data that would support a European CE mark for the CoStar paclitaxel-eluting stent
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.